Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
How the Acquisition Is Reshaping Mersana Therapeutics' Story and Analyst Outlook [Yahoo! Finance]
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.